These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25139839)

  • 1. Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
    Shankar GN; Alt C
    J Antimicrob Chemother; 2014 Dec; 69(12):3282-93. PubMed ID: 25139839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
    Moss JA; Malone AM; Smith TJ; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Vincent KL; Motamedi M; Friend DR; Clark MR; Baum MM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):875-82. PubMed ID: 22123689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.
    Andrei G; Lisco A; Vanpouille C; Introini A; Balestra E; van den Oord J; Cihlar T; Perno CF; Snoeck R; Margolis L; Balzarini J
    Cell Host Microbe; 2011 Oct; 10(4):379-89. PubMed ID: 22018238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SR-2P vaginal microbicide gel provides protection against herpes simplex virus 2 when administered as a combined prophylactic and postexposure therapeutic.
    Fields SA; Bhatia G; Fong JM; Liu M; Shankar GN
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5697-704. PubMed ID: 26149989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
    Vibholm L; Reinert LS; Søgaard OS; Paludan SR; Østergaard L; Tolstrup M; Melchjorsen J
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1404-11. PubMed ID: 22867119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
    Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
    J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
    Nixon B; Jandl T; Teller RS; Taneva E; Wang Y; Nagaraja U; Kiser PF; Herold BC
    Antimicrob Agents Chemother; 2014; 58(2):1153-60. PubMed ID: 24323471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge.
    Hsu M; Aravantinou M; Menon R; Seidor S; Goldman D; Kenney J; Derby N; Gettie A; Blanchard J; Piatak M; Lifson JD; Fernández-Romero JA; Zydowsky TM; Robbiani M
    AIDS Res Hum Retroviruses; 2014 Feb; 30(2):174-83. PubMed ID: 24117013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.
    Abdool Karim SS; Abdool Karim Q; Kharsany AB; Baxter C; Grobler AC; Werner L; Kashuba A; Mansoor LE; Samsunder N; Mindel A; Gengiah TN;
    N Engl J Med; 2015 Aug; 373(6):530-9. PubMed ID: 26244306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reformulated tenofovir gel for use as a dual compartment microbicide.
    Dezzutti CS; Rohan LC; Wang L; Uranker K; Shetler C; Cost M; Lynam JD; Friend D
    J Antimicrob Chemother; 2012 Sep; 67(9):2139-42. PubMed ID: 22581908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
    Wilson SS; Cheshenko N; Fakioglu E; Mesquita PM; Keller MJ; Herold BC
    Antivir Ther; 2009; 14(8):1113-24. PubMed ID: 20032541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: mechanism of antiviral action.
    Ceña-Diez R; Vacas-Córdoba E; García-Broncano P; de la Mata FJ; Gómez R; Maly M; Muñoz-Fernández MÁ
    Int J Nanomedicine; 2016; 11():2147-62. PubMed ID: 27274240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical microbicides for prevention of sexually transmitted infections.
    Obiero J; Mwethera PG; Wiysonge CS
    Cochrane Database Syst Rev; 2012 Jun; (6):CD007961. PubMed ID: 22696373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
    Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
    J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation development and evaluation of innovative two-polymer (SR-2P) bioadhesive vaginal gel.
    Podaralla S; Alt C; Shankar GN
    AAPS PharmSciTech; 2014 Aug; 15(4):928-38. PubMed ID: 24781671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Anti-Human Immunodeficiency Virus Drug Tenofovir, a Reverse Transcriptase Inhibitor, Also Targets the Herpes Simplex Virus DNA Polymerase.
    Andrei G; Gillemot S; Topalis D; Snoeck R
    J Infect Dis; 2018 Feb; 217(5):790-801. PubMed ID: 29186456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of coitally administered tenofovir 1% gel, a vaginal microbicide, in chronic hepatitis B virus carriers: results from the CAPRISA 004 trial.
    Baxter C; Yende-Zuma N; Tshabalala P; Abdool Karim Q; Abdool Karim SS
    Antiviral Res; 2013 Sep; 99(3):405-8. PubMed ID: 23832086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicides.
    Kenney J; Derby N; Aravantinou M; Kleinbeck K; Frank I; Gettie A; Grasperge B; Blanchard J; Piatak M; Lifson JD; Zydowsky TM; Robbiani M
    AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1117-24. PubMed ID: 25354024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.
    Segarra TJ; Fakioglu E; Cheshenko N; Wilson SS; Mesquita PM; Doncel GF; Herold BC
    PLoS One; 2011; 6(11):e27675. PubMed ID: 22096611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (4-styrenesulfonic acid-co-maleic acid) is an entry inhibitor against both HIV-1 and HSV infections - potential as a dual functional microbicide.
    Qiu M; Chen Y; Song S; Song H; Chu Y; Yuan Z; Cheng L; Zheng D; Chen Z; Wu Z
    Antiviral Res; 2012 Nov; 96(2):138-47. PubMed ID: 22940611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.